Compare CVEO & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVEO | CMPX |
|---|---|---|
| Founded | 1977 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 382.5M | 371.0M |
| IPO Year | 2013 | 2020 |
| Metric | CVEO | CMPX |
|---|---|---|
| Price | $34.81 | $1.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $37.00 | $14.57 |
| AVG Volume (30 Days) | 75.8K | ★ 4.3M |
| Earning Date | 05-01-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.72 | N/A |
| Revenue Next Year | $5.61 | $934.41 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $19.75 | $1.61 |
| 52 Week High | $36.50 | $6.88 |
| Indicator | CVEO | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 58.21 | 34.70 |
| Support Level | $20.44 | $1.68 |
| Resistance Level | $36.41 | $2.02 |
| Average True Range (ATR) | 1.24 | 0.16 |
| MACD | -0.15 | 0.08 |
| Stochastic Oscillator | 54.72 | 11.11 |
Civeo Corp provides hospitality services to the natural resources industry in Canada, Australia. The company provides a full suite of services for guests, including lodging, catering and food service, housekeeping and maintenance at accommodation facilities that the company or its customers own. The company provides services that support the day-to-day operations of these facilities, such as laundry, facility management and maintenance, water and wastewater treatments, power generation, communication systems, security and logistics. The company operates in active oil, metallurgical coal, liquefied natural gas and iron ore-producing regions. The company operates in three reportable business segments Canada, and Australia. It derives maximum revenue from Australia.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.